High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.

about

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.

Item

http://www.wikidata.org/entity/Q40063998

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

High ten-year remission rates ...... Results of a randomized Study.

@en

type

Item

label

High ten-year remission rates ...... Results of a randomized Study.

@en

prefLabel

High ten-year remission rates ...... Results of a randomized Study.

@en

P1476

High ten-year remission rates ...... Results of a randomized Study.

@en

P2093

Ana Ayala

http://www.w3.org/2001/XMLSchema#string

Andre H Goy

http://www.w3.org/2001/XMLSchema#string

Eleanor Neal

http://www.w3.org/2001/XMLSchema#string

Felipe Samaniego

http://www.w3.org/2001/XMLSchema#string

Fredrick B Hagemeister

http://www.w3.org/2001/XMLSchema#string

Jorge E Romaguera

http://www.w3.org/2001/XMLSchema#string

Lei Feng

http://www.w3.org/2001/XMLSchema#string

Loretta J Nastoupil

http://www.w3.org/2001/XMLSchema#string

Luis Fayad

http://www.w3.org/2001/XMLSchema#string

Maria A Rodriguez

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype

Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)

The indolent B-cell lymphomas.

Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

P304

263-270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14541

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P50

Fernando Cabanillas

Jason R Westin

P577

2017-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28340281

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

5901692

http://www.w3.org/2001/XMLSchema#string